Facts
as of Nov 22, 2026
Relay Therapeutics® puts protein motion at the heart of drug discovery to dramatically expand therapeutic possibilities.
It is hiring: 12 open roles, 4 of them posted in the last 30 days.
- Legal name
- Relay Therapeutics, Inc.
- Headquarters
- Cambridge, United States
- Employees
- 192US Form 5500 (plan participants) · Dec 2025 · -26% in a year
- Subsidiaries
- 1 in 1 countryUnited States 1 · SEC 10-K Exhibit 21
- Listing
- NASDAQ: RLAY
- Open roles
- 12Alion job postings
As of Nov 22, 2026, Alion lists 12 open roles at Relay Therapeutics. Relay Therapeutics is headquartered in Cambridge, United States. The median pay stated in its open roles is $233k, across 11 postings that state pay.
Sources: company registers, GLEIF, Wikidata, the company's site, Alion job postingsReport a mistake
Relay Therapeutics: 2 money records, each linked to its source.
$410kCapital expenditureFY2025
Revenue by yearas filed, with the net income
2025$15.4Mnet income −$276.5M
2024$10Mnet income −$337.7M
2023$25.5Mnet income −$342M
2022$1.4Mnet income −$290.5M
Every row links its own source. A flow two sources state counts once; a figure a source does not state reads "not stated".
Relay Therapeutics operates through 1 legal entity in 1 country.
Legal entities1 in 1 country
Relay Therapeutics, Inc.
operator
US
Holders and shares as each register or filing states them.
12 open roles, 4 of them posted in the last 30 days.
12Open roles4 posted in 30 days
$233kMedian advertised pay$203k – $275k
60 daysTime to fillmarket: 31 days
192EmployeesUS Form 5500 (plan participants) · Dec 2025 · -26% in a year
Head countas filed and stated
Where the openings areshare of open roles
Biotech43%
Leadership7%▼
Analytics7%▼
Finance7%▼
HR7%▲
Open roles over time−100%
Sep 21This week
Open roles a week: 9 then, 0 now
Source: the company's careers site, read by Alion several times a day; market medians from all open roles of the same family
Relay Therapeutics has 5 clinical trials on record, 4 under way.
Clinical trials
A First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid Tumors
phase 2 · under way · 180 participants · Advanced NRAS-Mutant Melanoma; Advanced NRAS-Mutant Solid Tumors; NRAS Mutation…
Mar 2026
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic P…
phase 3 · under way · 540 participants · PIK3CA Mutation; HER2- Negative Breast Cancer; Hormone Receptor Positive Tumor;…
Aug 2025
A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Sp…
phase 2 · under way · 277 participants · PIK3CA-Related Overgrowth Spectrum (PROS); Lymphatic Malformations; Vascular Ma…
Jun 2025
Biggest buyers1 · $29k
Fakultní nemocnice v Motole
Czech Republic · 1 public contract
$29k
Source: each app’s App Store and Google Play page (an app counts as the company’s when its developer site is on the company’s domain); the products its own site names.
Relay Therapeutics: 103 research papers in five years.
Legal entity active
Relay Therapeutics, Inc.
Not checked
Sanctions lists
OFAC SDN, EU consolidated
No match
Phishing reports
OpenPhish, Phishing.Database
None
Layoff notices
US WARN notices on file
None
Sources: company registers, the Alion truth index, OFAC and EU sanctions lists, US WARN notices
Milestones
Team shrank to 192 was 261 · US Form 5500 (plan participants)
2025
Sources: the outlets named on each headline, each story once
Footprint
Hiring in 1 city in 1 country.
1Cities
1Countries
CambridgeBusiest site
Source: office addresses in postings and company registers
Peers
Ranked #1 by open roles among its 11 closest peers.
Source: Alion's similar-companies engine (industry segments, technologies, headquarters country, size)